Shots:

• The discontinuation of P-III study is due to the inability of Fremanezumab to meet its 1EPs i.e- reduction in weekly number of cluster headache attacks in 4wks.
• In Jun’18- Teva also discontinued Enforce Program including a chronic cluster headache study assessing Fremanezumab due to its unmeet 1EP i.e- reduction in average no. of cluster headache attacks during the 12-wks. 
• Fremanezumab is a mAb- targeting calcitonin gene-related peptide (CGRP) ligand and block its binding with the receptor and is currently evaluating in P-II trial for post-traumatic headache

Ref: Teva | Image: Press Release Distribution